Exploratory development of thymosin alpha 1 for nasopharyngeal carcinoma therapy
AIM: To evaluate the effect of thymosin alpha 1 (Tα1) for nasopharyngeal carcinoma therapy. METHODS: A total of 42 nasopharyngeal carcinoma patients who visited The Affiliated Tumor Hospital of Xinjiang Medical University during the time from 2007-03 to 2008-12 and underwent initial treatment after definite diagnose by patholog were included in the study, randomly divided into chemoradiotherapy with Tα1 group (Tα1 group) and chemoradiotherapy group (Control group). To detect the number of specific cytotoxicity t lymphocyte (CTL) secreting IFN-γ in peripheral blood by ELISPOT methods before chemoradiotherapy and after chemoradiotherapy for 3 months, to compare the short-time effect, acute reaction of skin and mucosa, myelosuppression between the 2 groups, and to analyze the variation in immunological function after using immunopotentiator. RESULTS: The number of specific CTL secreting IFN-γ existed significant differences (P ＜ 0.05) before chemoradiotherapy and after chemoradiotherapy for 3 months in the 2 groups; There was no statistical significance between the 2 groups in the number of specific CTL before chemoradiotherapy and after chemoradiotherapy for 3 months, but the number of specific CTL in Tα1 group were more than Control group. Acute reaction of skin and mucosa existed significant differences between the two groups, but reversed in myelosuppression. CONCLUSION: Chemoradiotherapy combind with Tal may help improve the specific cell immunocompetence and reduce the acute reaction of skin and mucosa for nasopharyngeal carcinoma.
nasopharyngeal carcinomathymosin α-1intensity modulation radiated therapycellular immune function
NETL
NSTL
万方数据
维普
